260 related articles for article (PubMed ID: 27400447)
1. Surrogate end points for overall survival in breast cancer trials: A review.
Fiteni F; Bonnetain F
Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
[TBL] [Abstract][Full Text] [Related]
2. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
3. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies.
Berruti A; Amoroso V; Gallo F; Bertaglia V; Simoncini E; Pedersini R; Ferrari L; Bottini A; Bruzzi P; Sormani MP
J Clin Oncol; 2014 Dec; 32(34):3883-91. PubMed ID: 25349292
[TBL] [Abstract][Full Text] [Related]
4. Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
Petrelli F; Tomasello G; Barni S
Eur J Cancer; 2017 May; 76():8-16. PubMed ID: 28262586
[TBL] [Abstract][Full Text] [Related]
5. Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer.
Korn EL; Sachs MC; McShane LM
Ann Oncol; 2016 Jan; 27(1):10-5. PubMed ID: 26489443
[TBL] [Abstract][Full Text] [Related]
6. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
7. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis.
Conforti F; Pala L; Sala I; Oriecuia C; De Pas T; Specchia C; Graffeo R; Pagan E; Queirolo P; Pennacchioli E; Colleoni M; Viale G; Bagnardi V; Gelber RD
BMJ; 2021 Dec; 375():e066381. PubMed ID: 34933868
[TBL] [Abstract][Full Text] [Related]
9. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors.
Michiels S; Saad ED; Buyse M
Drugs; 2017 May; 77(7):713-719. PubMed ID: 28337673
[TBL] [Abstract][Full Text] [Related]
10. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
11. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
Petrelli F; Tomasello G; Ghidini M; Lonati V; Passalacqua R; Barni S
HPB (Oxford); 2017 Nov; 19(11):944-950. PubMed ID: 28764887
[TBL] [Abstract][Full Text] [Related]
12. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.
Ciani O; Davis S; Tappenden P; Garside R; Stein K; Cantrell A; Saad ED; Buyse M; Taylor RS
Int J Technol Assess Health Care; 2014 Jul; 30(3):312-24. PubMed ID: 25308694
[TBL] [Abstract][Full Text] [Related]
13. Surrogacy Beyond Prognosis: The Importance of "Trial-Level" Surrogacy.
Buyse M; Saad ED; Burzykowski T; Regan MM; Sweeney CS
Oncologist; 2022 Apr; 27(4):266-271. PubMed ID: 35380717
[TBL] [Abstract][Full Text] [Related]
14. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
[TBL] [Abstract][Full Text] [Related]
15. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
J Gastrointest Oncol; 2017 Feb; 8(1):39-48. PubMed ID: 28280607
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
[TBL] [Abstract][Full Text] [Related]
17. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
Li L; Pan Z
Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
[TBL] [Abstract][Full Text] [Related]
18. Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis.
Su F; Yang X; Yin J; Shen Y; Tan L
Ann Surg Oncol; 2023 Nov; 30(12):7461-7471. PubMed ID: 37400616
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness and relevance of intermediate endpoints for cytotoxic neoadjuvant therapy.
Fontanella C; Loibl S; von Minckwitz G
Breast; 2015 Nov; 24 Suppl 2():S84-7. PubMed ID: 26279131
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
